Abstract

[18] LAPTM4B down-regulation also down-regulated several cancer-related proteins in cervical cancer cells, including VEGF, cyclin-dependent kinase 12, hypoxia inducible factor 1 subunit alpha, MMP-2, and MMP-9 and dramatically blocked VEGF expression. [27] Thus, LAPTM4B is involved in the PI3K/AKT signaling pathway, and plays a fundamental role in the activation of PI3K/AKT signaling. [...]the PI3K/AKT signaling pathway, in combination with LAPTM4B, may represent a target for the amelioration of multidrug resistance in cancer therapy. Promisingly, LAPTM4B may facilitate angiogenesis by boosting a crucial growth factor involved in cancer. [...]the LAPTM4B-VEGF axis may be a potential candidate target for cancer therapy.

Details

Title
Lysosomal-associated protein transmembrane-4 beta: a novel potential biomarker for cancer therapy with multiple functions
Author
Xi-Chao, Xu 1 ; Jian-Guo, Feng 2 ; Li-Ling, Tang 1 

 Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China 
 Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China 
Pages
38-40
Section
Medical Progress
Publication year
2021
Publication date
Jan 2021
Publisher
Lippincott Williams & Wilkins Ovid Technologies
ISSN
03666999
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2480943306
Copyright
Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.